Arphamid Therapeutics SAS
Arphamid develops therapeutics that keep cancer patients on life-saving treatment. We target debilitating complications that force patients to reduce or stop chemotherapy. Dimiracetam, a glutamate modulator (Phase 2-ready), prevents early symptoms of oxaliplatin neuropathy. RF4662 reduces breakthrough pain episodes via GPR103 antagonism (IND-ready). RF4442 addresses cachexia via GPR10 antagonism. We seek €25M to advance three value-inflection milestones toward a €3.5B market.
Date, time and room information
Tuesday, May 5, 13:45 - 15:00, room Singapore
Category
Emerging biotech company
Title of the presentation
Stopping Patients From Stopping Cancer Treatment: Novel Neuroscience Therapies Transforming Cancer Supportive Care
Speaker information
| Name | Position | Institution |
|---|---|---|
| Alexander Kraus | President & CEO | Arphamid Therapeutics SAS |
Host and event manager:
Logistics and marketing partner:
